Primary intracranial dural-based synovial sarcoma with an unusual SYT fluorescence in situ hybridization pattern

Clinical features and surgical outcomes of primary intracranial synovial sarcomas

OBJECTIVE

Primary intracranial synovial sarcomas (PISSs) are extremely rare, with only 30 reported cases in the literature. The aim of this study is to outline the clinical characteristics of PISSs, examine prognostic risk factors, and attempt to develop an optimal treatment strategy based on the available data.

METHODS

We included a total of 33 PISS cases, comprising 3 patients from our institution and 30 patients documented in the literature. We collated clinical data from these cases and conducted an analysis of prognostic risk factors using Cox proportional hazards models and Kaplan-Meier methods.

RESULTS

The cohort consisted of 21 males and 12 females, with an average age of 30.0 ± 18.5 years (ranging from 1 to 81 years). Among these cases, gross total resection (GTR) was performed in 21 (63.6 %) cases, non-GTR in 11 (33.3 %), and biopsy in 1 (3.0 %) case. Additionally, 25 patients (78.1 %) received RT (Radiotherapy), and 6 patients (18.8 %) underwent CT (Chemotherapy). Over a mean follow-up period of 11.5 ± 14.1 months (ranging from 2 to 84 months), tumor recurrence was observed in 27 patients (90 %), and 21 patients (70 %) died, with an average follow-up duration of 18.9 ± 21.6 months (ranging from 2 to 105 months). Multivariate Cox regression analysis revealed that non-GTR and no RT was independent adverse factors for both PFS (Progression-Free Survival) and OS (Overall Survival). Kaplan-Meier analysis revealed that non-GTR (p = 0.0001) and the absence of radiotherapy (p < 0.0001) were predictive of shorter OS.

CONCLUSION

In our study, we observed that PISSs predominantly affect young males, and the prognosis of this disease is relatively poor. Our statistical analysis revealed that GTR and postoperative radiotherapy are beneficial for both PFS and OS. Therefore, we recommend GTR combined with postoperative radiotherapy as the standard treatment approach.

Olfactory groove monophasic sinovial sarcoma and von Recklinghausen's disease: A case report and literature review

BACKGROUND

Soft-tissue sarcomas are a rare and diverse group of neoplastic lesions. They represent only 1% of malignant tumors in adults and 15% in children. Synovial sarcoma (SS) is a type of soft-tissue sarcoma, accounting for 5-10% of cases, and commonly affecting extremities. Diagnosis, treatment, and prognosis remain challenging especially when localized in uncommon areas, such as intracranial lesions.

CASE DESCRIPTION

A 13-year-old male patient with a clinical history of neurofibromatosis Type I (NF1) presenting holocranial headache with jet vomiting and apathy 2 days before admission, without neurological deficits and/or focal findings. On magnetic resonance imaging: an extra-axial infiltrative lesion with contrast uptake at the base of the skull in the olfactory groove topography. After total tumor resection, the anatomopathological examination showed monophasic SS. The patient returned after 6 months with similar symptoms, and the lesion recurred and was reoperated. Unfortunately, 7 months after the second surgery, the patient died.

CONCLUSION

SS can occur extraarticulously and with a variable clinical presentation and poor prognosis despite adjuvant therapies with radiotherapy and chemotherapy. In individuals with clinical history of NF1, there is still no direct correlation between the two manifestations, although current descriptions are suggestive of a possible interaction.

A Case of Poorly Differentiated Synovial Sarcoma Arising in a Nasal Cavity Radiation Field: An Unusual Tumor in an Unusual Location

Synovial sarcomas are high-grade soft tissue sarcomas of primitive mesenchymal origin which are defined by a pathognomonic t(X;18)(p11,q11) translocation, and which occur in pediatric and adult populations. Herein we report a case of a 33-year-old female with a history of nasopharyngeal carcinoma status post radiotherapy, presenting with a poorly differentiated synovial sarcoma of the nasal cavity arising in the radiation field. While the development of radiation-associated sarcoma is a known complication of radiotherapy, to date only 10 cases of synovial sarcoma have been reported to occur in previously irradiated tissues. Moreover, only 1 case of poorly differentiated synovial sarcoma involving the nasopharynx has been described.

Primary intracranial synovial sarcoma: A case report and review of literature

Background:

Primary intracranial synovial sarcomas (PrISS) are unusual dural based mesenchymal tumors seen most commonly in the supratentorial compartment. They can mimic a spontaneous intracranial hemorrhage or a high-grade glioma on imaging.

Case Description:

A 31-year-old male presented with headache and right hemiparesis for 2 weeks. CT brain revealed a left frontal spontaneous intracerebral hemorrhage. PrISS revealed a heterogeneously ring enhancing solid cystic lesion with attachment to convexity dura. Intraoperatively, it mimicked a high-grade glioma. Histopathology report showed features of a synovial sarcoma, which was later confirmed with IHC. Classical SYT-SSX2 translocation was confirmed only on RTPCR after fluorescent in situ hybridization (FISH) was negative for same. Whole body positron emission tomography (PET-CT) did not show any extracranial tumor. Despite radiotherapy, there were recurrence and tumor progression at 6 months and the patient succumbed 11 months later.

Conclusion:

PrISS is an unusual aggressive intracranial neoplasm that carries a worse prognosis when compared nonintracranial synovial sarcomas. Molecular cytogenetics (FISH and RTPCR) are essential for confirming the diagnosis, though FISH seems to have a lower sensitivity and can yield false negative results as was noted in this case.

Intracranial primary synovial sarcoma mimicking a spontaneous cerebral hematoma-a case report and review of the literature

BACKGROUND

Synovial sarcoma is a soft tissue sarcoma, of uncertain histological origin, usually located near large joints and concerning mainly young adults. Intracranial presentation in the form of metastasis from a primitive body sarcoma has been rarely reported. However, intracranial primitive synovial sarcoma (IPSS) is extremely rare and only a few cases have been reported in the literature.

CASE DESCRIPTION

We present the case of a 48-year-old man, with no particular medical history, that was referred to our hospital for severe headache with a normal neurological exam and a CT cerebral scan showing a left frontal lobe hematoma. The initial cerebral CT scan didn't show any vascular malformation and the body CT scan was negative for a primitive lesion. A close follow-up with a cerebral MRI three months later, demonstrated a T1 enhanced lesion with an important volume progression. The patient underwent a complete surgical removal of this lesion and the first pathology diagnosis was compatible with a meningioma. After further proofreading by an expert and molecular analysis, the diagnosis of monophasic synovial sarcoma was confirmed. Nine months after the first surgery, the follow-up MRI showed the progressive recurrence of the lesion and in this context the patient underwent a second surgery with total resection of the tumor and frontal thin margin excision. Afterwards, the patient was treated with adjuvant radiotherapy, with a good clinical evolution, and till now the follow-up shows no recurrence.

CONCLUSION

IPSS is an extremely rare sarcoma, with challenging diagnosis and difficult management. Specific molecular analysis is necessary. Complete resection followed by radiotherapy seem to be the most appropriate therapeutic approach. However, the prognosis is still poor. Our case is even rarer because of the initial presentation as a cerebral hematoma.

Primary synovial sarcoma of the scalp: Report of case with a clinicopathological and molecular cytogenetic study

Synovial sarcoma (SS) arising primarily in the scalp was scarcely reported. Here we described a subcutaneous mass in the right parietal region of the scalp of a 39year-old male patient. It has been present for 10years and enlarged recently. It was initially suspected as hemangioma by magnetic resonance imaging (MRI), but the histological examination revealed a sarcoma rich of spindle cells reminiscent of SS. Therefore, immunohistochemistry, florescence in site hybridization (FISH), reverse transcription-polymerase chain reaction (RT-PCR) and DNA sequencing were performed to determine the final diagnosis as biphasic SS. The detailed description of primary scalp SS might help differential diagnosis of scalp soft tumors.

Synovial sarcoma: defining features and diagnostic evolution

Synovial sarcoma (SS) is a malignant mesenchymal neoplasm with variable epithelial differentiation, with a propensity to occur in young adults and which can arise at almost any site. It is generally viewed and treated as a high-grade sarcoma. As one of the first sarcomas to be defined by the presence of a specific chromosomal translocation leading to the production of the SS18-SSX fusion oncogene, it is perhaps the archetypal "translocation-associated sarcoma," and its translocation remains unique to this tumor type. Synovial sarcoma has a variety of morphologic patterns, but its chief forms are the classic biphasic pattern, of glandular or solid epithelial structures with monomorphic spindle cells and the monophasic pattern, of fascicles of spindle cells with only immunohistochemical or ultrastructural evidence of epithelial differentiation. However, there is significant morphologic heterogeneity and overlap with a variety of other neoplasms, which can cause diagnostic challenge, particularly as the immunoprofile is varied, SS18-SSX is not detected in 100% of SSs, and they may occur at unusual sites. Correct diagnosis is clinically important, due to the relative chemosensitivity of SS in relation to other sarcomas, for prognostication and because of the potential for treatment with specific targeted therapies in the near future. We review SS, with emphasis on the diagnostic spectrum, recent immunohistochemical and genetic findings, and the differential diagnosis.

Clinical Neuropathology practice guide 6-2013: morphology and an appropriate immunohistochemical screening panel aid in the identification of synovial sarcoma by neuropathologists

Aims: Pathologists are under increasing pressure to accurately subclassify sarcomas, yet neuropathologists have limited collective experience with rare sarcoma types such as synovial sarcoma. We reviewed 9 synovial sarcomas affecting peripheral nerve diagnosed by neuropathologists and explored the morphologic and immunohistochemical differences between these and MPNST. Our goal was to make practical recommendations for neuropathologists regarding which spindle cell tumors affecting nerve should be sent for SYT-SSX testing. Methods: Clinical records and genetics were reviewed retrospectively and central pathology review of 9 synovial sarcomas and 6 MPNST included immunohistochemistry for SOX10, S100, BAF47, CK (lmw, pan, CK7, CK19), EMA, CD34, bcl2, CD99, and neurofilament. Results: Common synovial sarcoma sites were brachial plexus, spinal and femoral nerve, none were “intra-neural”, all had the SYT-SSX1 translocation, and 6/9 were monophasic with myxoid stroma and distinct collagen. Half of the monophasic synovial sarcomas expressed CK7, CK19 or panCK in a “rare positive cells pattern”, 8/9 (89%) expressed EMA, and all were SOX10 immunonegative with reduced but variable BAF47 expression. Conclusions: We recommend that upon encountering a cellular spindle cell tumor affecting nerve neuropathologists consider the following: 1) SYT-SSX testing should be performed on any case with morphology suspicious for monophasic synovial sarcoma including wiry or thick bands of collagen and relatively monomorphous nuclei; 2) neuropathologists should employ a screening immunohistochemical panel including one of CK7, panCK or CK19, plus EMA, S100 and SOX10, and 3) SYT-SSX testing should be performed on any spindle cell tumor with CK and/or EMA immunopositivity if SOX10 immunostaining is negative or only labels entrapped nerve elements.

Gone FISHing: clinical lessons learned in brain tumor molecular diagnostics over the last decade

Fluorescence in situ hybridization (FISH) is a powerful, morphology-based technique to assess targeted copy number alterations or gene rearrangements in formalin-fixed, paraffin-embedded tissues. It has a wide range of applications in routine clinical contexts to identify cytogenetic biomarkers for more accurate diagnosis and prognostic stratification. This review and update addresses practical uses of FISH as a molecular diagnostic tool in the setting of brain tumors, including gliomas, embryonal neoplasms, ependymomas and meningiomas, focusing on key genetic biomarkers, such as 1p19q codeletion, epidermal growth factor receptor (EGFR) gene amplification, BRAF rearrangement and many others. Also discussed are lessons learned over the past decade, including common technical issues to consider when implementing and interpreting FISH results in a clinical setting.